Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy

Clinical Trial ID NCT02994303

Rank	Title	Journal	Year	PubWeight™‹?›
1	Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.	Kidney Int	2010	1.25
2	Fabry disease: dose matters.	J Am Soc Nephrol	2014	0.97
3	Renal complications of Fabry disease in children.	Pediatr Nephrol	2012	0.93
4	Assessment of renal pathology and dysfunction in children with Fabry disease.	Clin J Am Soc Nephrol	2010	0.84
5	The management and treatment of children with Fabry disease: A United States-based perspective.	Mol Genet Metab	2015	0.81
6	Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.	PLoS One	2015	0.81
7	Quantitating glomerular endothelial fenestration: an unbiased stereological approach.	Am J Nephrol	2011	0.78
8	Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.	PLoS One	2014	0.78
9	Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.	Mol Genet Metab	2016	0.76
10	AJKD Atlas of Renal Pathology: Fabry Nephropathy.	Am J Kidney Dis	2015	0.75
11	Implications of early renal changes in Fabry disease.	Clin Ther	2008	0.75
12	One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.	PLoS One	2016	0.75